Previous 10 | Next 10 |
Oyster Point Pharma (NASDAQ:OYST) will implement a cost-savings plan that it says will lead to $6M-$8M in savings this year but also includes laying off up to 50 workers. The ophthalmic diseases focused biotech said it expects savings of $40M-$48M in 2023. Oyster Point said that the move will...
Plan to Continue to Drive TYRVAYA ® Launch with Approximately 150-200 Field-Based Sales Resources Plan Expected to Deliver Expense Savings of Approximately $6-8 Million in the Second Half of 2022 and $40-48 Million in 2023 Company to Refocus Research and D...
PRINCETON, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced tha...
Oyster Point Pharma, Inc. (OYST) Q1 2022 Earnings Conference Call May 5, 2022, 4:30 PM ET Company Participants Arty Ahmed - Vice President, Investor Relations Dr. Jeffrey Nau - President and CEO Dan Lochner - Chief Financial Officer John Snisarenko - Chief Commercial Officer Conference Call P...
Image source: The Motley Fool. Oyster Point Pharma, Inc. (NASDAQ: OYST) Q1 2022 Earnings Call May 05, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Oyster Point Pharma, Inc. (OYST) Q1 2022 Earnings Call Transcript...
TYRVAYA ® Nasal Spray Net Product Revenue of $2.7 Million in Q1’22 Approximately 19,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 4,500 Unique Eye Care Professionals Expansion of Commercial Coverage fo...
PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that i...
PRINCETON, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced th...
PRINCETON, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced th...
OKYO Pharma is a UK based developer of next generation ocular therapeutics based on GPCR and MRGPR. The company plans direct Phase 2 trial of its lead candidate following a pre-IND meeting with FDA. The company has filed F-1 for an IPO of its ADSs. For further details see: ...
News, Short Squeeze, Breakout and More Instantly...
Oyster Point Pharma Inc. Company Name:
OYST Stock Symbol:
NASDAQ Market:
Oyster Point Pharma Inc. Website:
TYRVAYA ® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3 ’ 22 Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care Profes...
Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”), ...